Comparison
A 503B outsourcing facility vs a drug manufacturer
The dividing line is not manufacturing standards, because both sit under current good manufacturing practice: section 353b exempts an outsourcing facility from adequate directions for use and from new drug approval, but not from the manufacturing-practice requirement. The line is what reaches the market. A manufacturer sells a product reviewed and approved before marketing; an outsourcing facility supplies a compounded preparation that was never reviewed. Several states license the second as a manufacturer regardless, because they have no other category for it.
What separates them?
What reaches the market, not how carefully it was made.
This is the part that surprises people who assume the difference is a quality gradient. FDA's own description, contrasting the two pathways, is that outsourcing facilities are "subject to CGMP requirements." Section 353b exempts a compounded drug from labelling with adequate directions for use and from new drug approval — it does not exempt it from the manufacturing-practice requirement.
So the manufacturing standard is shared. What is not shared is review. A manufacturer's product was evaluated before marketing; a compounded preparation was not, whichever facility made it. That single fact is the whole boundary, and everything below is a consequence of it.
The comparison
| Facility registered under section 503B | Conventional drug manufacturer | |
|---|---|---|
| What it puts on the market | A compounded preparation | A product approved before marketing |
| Pre-market review of the item | None — § 353b exempts it from the approval requirement | Reviewed and approved |
| Current good manufacturing practice | Applies; § 353b does not exempt it | Applies |
| Federal status | Elects to register with FDA as an outsourcing facility | Not addressed here — see caveats |
| Must be a licensed pharmacy | No; § 353b(d)(4) is explicit that it need not be | No |
| Patient-specific prescription | May or may not obtain one | Not applicable |
| Registration cycle with FDA | Annually, between 1 October and 31 December | Not addressed here |
| Product reporting to FDA | On initial registration and semi-annually, in June and December | Not addressed here |
| FDA inspection | On a risk-based schedule, considering compliance history, recalls, inherent drug risk and shortage-list status | Not addressed here |
| Drug supply chain security requirements | Exempt | Not addressed here |
| Can be described as FDA-approved or FDA-licensed | No — no such designation exists for either compounding entity type | The product can be described as approved; the firm is not "FDA-approved" |
Why do states license an outsourcing facility as a manufacturer?
Because several of them have no other category, and they say so in their rule text.
Arizona is the clearest case in our set: the strings "outsourcing" and "503B" do not appear in its board rules at all, and a facility registered under section 503B is permitted as a drug manufacturer. Arizona's amended rules, effective 5 September 2026, make that explicit by referring to "an outsourcing facility permitted as a manufacturer operating under Section 503B of the Federal Food, Drug, and Cosmetic Act."
North Carolina does something similar in its statutory definition, describing an outsourcing facility as "a manufacturer at a single geographic location or address that is engaged in the compounding of sterile drugs, has elected to register as an outsourcing facility with the Food and Drug Administration, and complies with the requirements as provided in 21 U.S.C. § 353b" — and registers it alongside wholesalers, manufacturers and repackagers with the Commissioner of Agriculture. Texas routes it through a wholesale drug distribution licence required "for each place of business."
Does that mean the two are the same thing?
No. It means the state's licensing vocabulary is coarser than the federal category.
This is worth holding onto because it produces a genuine confusion in the market. A facility can hold something that says "manufacturer" on it in one state, "outsourcing facility" in another, and a wholesale distribution licence in a third, while being the same entity doing the same thing. The label on the state credential describes the state's permit scheme, not what the facility is allowed to sell.
The federal definition is the stable one. Section 353b(d)(4) describes a facility at one geographic location engaged in the compounding of sterile drugs, that has elected to register, and that complies with the section. Two clarifications in that definition do most of the practical work: it is not required to be a licensed pharmacy, and it may or may not obtain prescriptions for identified individual patients.
Where does manufacturing practice put them on the same footing?
In at least one state's regulation, on its face — and the mechanism is worth seeing.
New York deems a drug adulterated or misbranded if "it is not manufactured in accordance with the good manufacturing practices specified in Parts 210 and 211 of Title 21, Code of Federal Regulations," with a proviso for "a drug manufactured by a pharmacy for in-house use." A facility registered under section 353b is required to operate under those parts, so it satisfies the prong directly and never needs the proviso. New York also requires nonresident outsourcing facilities registered there to comply with 21 CFR Parts 210 and 211, be supervised by a New York-licensed pharmacist, and submit annual inspection results.
The same regime produces the dating difference. Under current good manufacturing practice, an expiration date "shall be determined by appropriate stability testing." That describes the kind of evidence behind the date. It is not a claim that any date is longer, and no number appears on this site.
What can you actually check about each?
For an outsourcing facility, a fair amount, and FDA publishes it. For a state-licensed compounding pharmacy, nothing federal — which is an asymmetry worth knowing before you assume otherwise.
FDA maintains a public table of registered outsourcing facilities. Its columns carry a Form 483 flag, a recall flag and the action taken after each facility's most recent inspection, alongside the initial and latest registration dates. That table listed 97 facilities as of the 28 August 2026 data lock; it is rebuilt weekly, so the figure is a snapshot and should never be repeated without its date. FDA separately publishes compounding inspections, recalls and other actions.
There is no federal equivalent for a 503A pharmacy. Those are state-licensed, and FDA maintains no comparable public inspection table for them, so diligence on a 503A runs through the state board and any accreditor instead. We link FDA's table rather than reproducing it: republishing named facilities alongside their inspection and recall values would be us asserting compliance statuses about third parties, which this site does not do.
Does federal registration let a facility ship into your state?
No, and this is the most consequential misreading in the whole area.
Section 353b is a federal exemption from federal law. It preempts nothing at the state level. In every state we read in full and were able to verify, an outsourcing facility needed a state credential in addition to its FDA registration — Georgia is the one state in our set where we could not verify the position either way. California's version comes with an annual on-site inspection reimbursed at the facility's expense.
A facility that satisfies section 353b in full and holds nothing in the destination state is not compliant; it is federally clean and state-exposed. That is a question to ask directly, state by state, and it is cheap to ask.
What can never be said about either?
That the facility is approved or licensed by FDA.
FDA's position is that "compounding facilities, including pharmacies and outsourcing facilities, are not 'FDA-approved' or 'FDA-licensed' entities. The FD&C Act does not establish an 'FDA-approved' or 'FDA-licensed' designation for pharmacies or outsourcing facilities." The only accurate construction for the compounding side is that a facility is registered with FDA as an outsourcing facility under section 503B.
Nor is registration a quality claim about any individual preparation. What section 353b requires is manufacturing-practice compliance, registration, reporting and inspection at the facility level. Describing a particular compounded preparation as safer or better on that basis is a claim the statute does not support, and this page does not make it.
How this comparison was made
From the statutory text, FDA's published material, and the state rules we read in full — with a deliberate hole in it.
The outsourcing-facility side is drawn from 21 U.S.C. § 353b, from FDA's compounding-law page and registered-facility table, and from the rules of the states read in full. The manufacturer side is drawn only from what compounding is exempted from and from what approval means, because a manufacturer's own regulatory obligations were not researched from primary sources. Rows in the table above marked "not addressed here" are genuinely not established by us, and are left empty rather than filled from memory.
No entity is named, assessed or ranked. All statements are as of 29 August 2026, except the FDA facility count, which is as of the 28 August 2026 data lock, and Arizona's incoming rule, which carries its own effective date of 5 September 2026.
Where to go from here
The pathway comparison a buyer usually needs first is 503A pharmacies and 503B outsourcing facilities compared. The object-level version of this page — a compounded preparation next to a commercially available product — is at compounded and commercially available compared, and the transaction that decides which pathway applies to you is at office stock and patient-specific fulfilment compared.
To have a supplier's federal registration and its state credentials checked against the states you actually ship to, you can apply for an account.